N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells-Reference-Cited by-同舟云学术

N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells

Published:2022-12 Issue: Volume:65 Page:100886
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Liu Zhihua,Zheng Nanxin,Li Juan,Li Chao,Zheng Dan,Jiang Xue,Ge Xiaoying,Liu Min,Liu Lianjie,Song Zhen,Bao Leilei,Zhan Yangyang^ORCID,Gao Xianhua

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference37 articles.

1. From Krebs to clinic: glutamine metabolism to cancer therapy;Altman;Nat. Rev. Cancer,2016

2. NCBI GEO: archive for functional genomics data sets--update;Barrett;Nucleic Acids Res.,2013

3. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN;Chong;Mol. Cancer,2022

4. Identifying and characterizing circRNA-protein interaction;Du;Theranostics,2017

5. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs;Dudekula;RNA Biol.,2016

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer;Drug Resistance Updates;2024-11

2. The interaction between m6A modification and noncoding RNA in tumor microenvironment on cancer progression;International Immunopharmacology;2024-10

3. KLF12 interacts with TRIM27 to affect cisplatin resistance and cancer metastasis in esophageal squamous cell carcinoma by regulating L1CAM expression;Drug Resistance Updates;2024-09

4. Role of N6‐methyladenosine RNA modification in cancer;MedComm;2024-09

5. A phosphoglycerate mutase 1 allosteric inhibitor restrains TAM-mediated colon cancer progression;Acta Pharmaceutica Sinica B;2024-09